Obseva (NASDAQ:OBSV) Given New $16.00 Price Target at Credit Suisse Group

Obseva (NASDAQ:OBSV) had its price target cut by Credit Suisse Group from $24.00 to $16.00 in a research report sent to investors on Monday, The Fly reports. They currently have an outperform rating on the stock.

Several other equities analysts have also recently issued reports on the company. HC Wainwright set a $44.00 target price on Obseva and gave the stock a buy rating in a research report on Wednesday, June 5th. Zacks Investment Research upgraded Obseva from a sell rating to a hold rating in a research report on Saturday, June 1st. ValuEngine cut Obseva from a buy rating to a hold rating in a research report on Wednesday, May 8th. Finally, Wedbush reiterated an outperform rating and set a $38.00 target price on shares of Obseva in a research report on Thursday, July 18th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $27.50.

NASDAQ OBSV traded up $0.26 on Monday, hitting $9.36. 2,342 shares of the company’s stock were exchanged, compared to its average volume of 47,329. The company has a current ratio of 6.73, a quick ratio of 6.73 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $10.53. Obseva has a fifty-two week low of $8.83 and a fifty-two week high of $19.40. The stock has a market cap of $417.93 million, a price-to-earnings ratio of -4.90 and a beta of 0.93.

Obseva (NASDAQ:OBSV) last released its earnings results on Thursday, May 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.09). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. As a group, equities analysts expect that Obseva will post -2.32 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. United Services Automobile Association grew its holdings in shares of Obseva by 132.3% in the 4th quarter. United Services Automobile Association now owns 26,480 shares of the company’s stock worth $335,000 after acquiring an additional 15,080 shares during the period. Barclays PLC grew its holdings in shares of Obseva by 331.1% in the 4th quarter. Barclays PLC now owns 10,118 shares of the company’s stock worth $128,000 after acquiring an additional 7,771 shares during the period. Wedbush Securities Inc. grew its holdings in shares of Obseva by 86.1% in the 1st quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock worth $496,000 after acquiring an additional 17,950 shares during the period. Fosun International Ltd acquired a new stake in shares of Obseva in the 1st quarter worth approximately $2,494,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Obseva in the 4th quarter worth approximately $159,000. Institutional investors and hedge funds own 63.58% of the company’s stock.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Story: What is a growth and income fund?

The Fly

Analyst Recommendations for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.